Replies to post #135348 on OWC Pharmaceutical Research Corp (OWCP)

[EasternTimeZone]

This current PPS is a strong support level after the price dropped as a result of initial fear from the SEC action against Jeffery Friedland. OWCP (OWC) was not named or implicated as a party to the pending SEC action against Friedland. Since the SEC Complaint was filed the case has gone before the judge and has several hearings on the docketed and nowhere is OWC or OWCP a party to these hearings. The assets of Jefferey Friedland and his wife have been frozen and the SEC will likely recovery several million dollars from the Friedlands.

Now that the case is moving forward and discovery will take place showing investors that OWCP was not a party to it, nor had any knowledge of it, this stock will move up sharply, you'll see.

OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
Mar 08, 2018, 10:31 ET

PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a chairman's statement to shareholders.

In the light of recent events, and the numerous communications we have received from shareholders, I would like to address this statement to the Shareholders of OWCP (the "Company").

The Company is committed to building a leadership position in the medical cannabis market and to our mission of improving patients' lives through the development of new solutions, products and devices derived from and delivery mechanisms for the use of medical cannabis.

We have recruited a highly skilled management team with multi-year experience in medical cannabis, pharmaceutical development, corporate management and capital markets.

As we have stated in our 8-K filing of today, we are neither a party to the pending SEC action against a former adviser to the Company, nor is the Company alleged to have been a party to nor had any knowledge of the purported scheme by the former adviser, who is the subject of the SEC action.

The Company's management is committed to and focused on our development programs which are continuing as per plan. These include inter alia, our current safety trial for our cannabis cream; the approval processes to initiate a safety trial for our oral disintegrating tablet and additional pipeline projects.

As a management team, we are committed to building value for our shareholders though professional, ethical and strategic management of a technology platform that we believe will bring improved health and quality of life to millions of patients around the world. We have recently announced the addition of our new Chief Scientific Officer and we continue to develop the resources we believe will bolster our endeavors in creating a great company.

Yours sincerely,

Dr. Stanley Hirsch
Chairman of the Board

$OWCP Long and Strong